Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients With DLBCL

NCT02734771 is registered in ClinicalTrials.gov with Patrick Reagan as lead sponsor.

NCT NCT02734771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02734771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients With DLBCL
Lead sponsor
Patrick Reagan
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2016
Completion date
December 31, 2025
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma